SNOA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sonoma Pharmaceuticals Inc (SNOA) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The technical indicators show bearish trends, there are no significant positive catalysts or trading signals, and the company's financial performance shows declining net income and EPS despite revenue growth. A hold is recommended until stronger signals or catalysts emerge.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 22.148, and moving averages suggest a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 2.349, with key support at 2.158 and resistance at 2.54.
Revenue increased by 22.03% YoY in Q3 2026, and gross margin improved by 6.48% YoY.
Net income dropped by 11.75% YoY, and EPS decreased by 23.81% YoY. No recent news or significant trading trends from hedge funds, insiders, or Congress. Technical indicators are bearish.
In Q3 2026, revenue grew to $4,349,000 (+22.03% YoY), but net income fell to -$819,000 (-11.75% YoY), and EPS dropped to -0.48 (-23.81% YoY). Gross margin improved to 37.94% (+6.48% YoY).
No analyst rating or price target changes available.
